News
Podcast Launch: Innovations in Immuno-Oncology
HanchorBio's new and original podcast series, Innovations in Immuno-Oncology, offer listeners a closer look at the scientific rationale, business strategy, and global licensing perspectives behind next-generation immuno-oncology drug development.
Mar 11, 2026
Read more
HanchorBio to Present Next-Generation Biologics Innovation at Biologics World Taiwan 2026
HanchorBio will participate in Biologics World Taiwan 2026, taking place on March 25–26, 2026, at Hilton Taipei Sinban, Taiwan. During the event, HanchorBio’s Chairman and Chief Executive Officer, Dr. Scott Liu, and Executive Director of CMC, Dr. Vivian Kuo, will be invited as speakers. They will share insights on next-generation biologics innovation, spanning immuno-oncology, tri-specific Fc fusion protein development, and process and CMC excellence for emerging drug modalities.
Mar 11, 2026
Read more
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress Early clinical data show 100% ORR at 5.12 mg/kg, 100% DCR across doses, and dose-dependent tumor shrinkage; the 12 mg/kg cohort remains ongoing HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology […]
Mar 05, 2026
Read more
HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026
BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo) will be held from March 12–14, 2026 in Suzhou, China. Dr. Scott Liu, Founder, Chairman and Chief Executive Officer of HanchorBio Inc., has been invited to attend the conference and will serve as a roundtable moderator at the Antibody Drug Innovation & Development Forum, as well as participate as a featured interview and discussion speaker.Interview Topic:
“Focused Strategies in Specialized Segments — Insights from BD Transactions on the Positioning and Collaborative Strategy of Bispecific and Multispecific Antibody Innovation”
Mar 02, 2026
Read more
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026 Monotherapy and multi-regimen combination data demonstrate a cytopenia-sparing safety profile, robust CD47 receptor occupancy, and encouraging dose-dependent antitumor activity HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical and translational data on HCB101, its […]
Feb 19, 2026
Read more
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026 Sustained execution and high-impact data across HanchorBio’s next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at […]
Feb 05, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation Mid-dose cohorts demonstrate ~80% ORR when HCB101 is layered on the standard ramucirumab and paclitaxel in second-line gastric cancer. HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today […]
Jan 09, 2026
Read more
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting
HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.
Apr 13, 2023
Read more